Beam Therapeutics Inc.
BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$31.75
Price-1.76%
-$0.57
1Y
Price
Market Cap
$3.266b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-320.1%
EBITDA Margin-297.2%
Net Profit Margin-411.9%
Free Cash Flow Margin-320.1%
EBITDA Margin-297.2%
Net Profit Margin-411.9%
Free Cash Flow MarginRevenue
$164.011m
+17.4%
1y CAGR+18.1%
3y CAGR+143.6%
5y CAGREarnings
-$65.040m
+18.7%
1y CAGR-28.9%
3y CAGR-8.2%
5y CAGREPS
-$0.68
+16.1%
1y CAGR-22.6%
3y CAGR-2.4%
5y CAGRBook Value
$1.164b
$1.481b
Assets$316.360m
Liabilities$250.822m
DebtDebt to Assets
16.9%
-4x
Debt to EBITDAFree Cash Flow
-$383.844m
-6.6%
1y CAGR-34.1%
3y CAGR-173.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company